Variations in amount of TSST-1 produced by clinical methicillin resistant Staphylococcus aureus (MRSA) isolates and allelic variation in accessory gene regulator (agr) locus by Nagao, Miki et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Microbiology
Open Access Research article
Variations in amount of TSST-1 produced by clinical methicillin 
resistant Staphylococcus aureus (MRSA) isolates and allelic variation 
in accessory gene regulator (agr) locus
Miki Nagao*1, Akira Okamoto2, Keiko Yamada2, Tadao Hasegawa2, 
Yoshinori Hasegawa3 and Michio Ohta2
Address: 1Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto, Japan, 2Department of Molecular Bacteriology, 
Nagoya City University Graduate School of Medical Science, Nagoya, Japan and 3Department of Respiratory Medicine, Nagoya University 
Graduate School of Medicine, Nagoya, Japan
Email: Miki Nagao* - mnagao@kuhp.kyoto-u.ac.jp; Akira Okamoto - yoh@med.nagoya-u.ac.jp; Keiko Yamada - yakeiko@med.nagoya-u.ac.jp; 
Tadao Hasegawa - tadaoh@med.nagoya-c-u.ac.jp; Yoshinori Hasegawa - yhasegawa@med.nagoya-u.ac.jp; Michio Ohta - mohta@med.nagoya-
u.ac.jp
* Corresponding author    
Abstract
Background: Staphylococcus aureus (S. aureus) is an important pathogen associated with both
nosocomial and community-acquired infections and its pathogenicity is attributed to its potential
to produce virulence factors. Since the amount of toxin produced is related to virulence, evaluating
toxin production should be useful for controlling S. aureus infection. We previously found that
some strains produce relatively large amounts of TSST-1; however, no reports have described the
amount of TSST-1 produced by clinical isolates.
Methods: Amounts of TSST-1 produced by clinical methicillin resistant S. aureus (MRSA) isolates
were measured by Western blotting. We determined their accessory gene regulator (agr) class by
PCR and investigated whether TSST-1 production correlates with variations in the class and
structure of the agr.
Results: We found that 75% of surveyed MRSA isolates (n = 152) possessed the tst gene and that
96.7% belonged to agr class 2. The concentrations of TSST-1 secreted into culture supernatants by
34 strains measured by Western blotting differed 170-fold. Sequencing the entire agr locus (n = 9)
revealed that some had allelic variations regardless of the amount of TSST-1 produced whereas
sequencing the sar, sigma factor B and the tst promoter region revealed no significant changes.
Conclusion: The amounts of TSST-1 produced by clinical MRSA isolates varied. The present
results suggest that TSST-1 production is not directly associated with the agr structure, but is
instead controlled by unknown transcriptional/translational regulatory systems, or synthesized by
multiple regulatory mechanisms that are interlinked in a complex manner.
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Background
Staphylococcus aureus (S. aureus) is responsible for many
nosocomial and community-acquired infections. Its patho-
genicity is attributed to its ability to produce many mem-
brane-associated components and extracellular substances,
several of which have been implicated as virulence factors
[1,2]. One of the most unique manifestations among the
various staphylococcal infections is staphylococcal toxic
shock syndrome (TSS). The associated toxin TSS toxin-1
(TSST-1) is encoded by the tst  gene, and might also be
involved in the genesis of some autoimmune diseases
[1,3,4]. The accessory gene regulator (agr) operon among
several potentially associated factors is thought to positively
regulate TSST-1 production [2,3]. The agr locus comprises 5
genes (AgrA, AgrB, AgrC, AgrD, and hld) that function in
both transcription and translation to regulate numerous tox-
ins, enzymes and cell surface proteins. A polymorphism in a
variable region of the agr  locus comprises nucleotide
sequences encoding AgrD, the C-terminal two-thirds of
AgrB, and a portion of the N-terminal half of AgrC, which
has led to the assignation of S. aureus isolates into four
classes [2,5]. In addition to the agr polymorphism, muta-
tions of wild-type S. aureus strains resulting in agr deletions
alter exoprotein biosynthesis [6]. However, the relationship
between the agr polymorphism and TSST-1 production is
unknown.
We previously analyzed images from two-dimensional
electrophoresis (2-DE) and found that two clinical methi-
cillin-resistant  S. aureus (MRSA) isolates produce rela-
tively large amounts of superantigenic exotoxins [7]. Since
the amount of toxins produced is probably directly related
to the virulence of S. aureus, evaluating the concentration
of toxins produced by each strain might be useful for con-
trolling infection.
The aim of this study was to determine whether TSST-1
production varies among clinical MRSA strains and
whether it is related to variations in agr class and structure.
Results
Detection of the tst gene and agr classes
We detected the tst gene in 115 (75.7%) of 152 strains
after PCR amplification. Among them, 53 of 66 strains
from the nation-wide collection (80.3%) and 62 isolated
from 86 blood samples (72.0%) harbored the gene. We
identified 147 of 152 isolates (96.7%) as agr class 2, and
3 isolates as agr class 1 (1.9%). We did not identify any
isolates of agr classes 3 or 4. The classes of 2 strains were
unidentifiable. Among 112 tst-positive strains, 111
belonged to agr class 2. These results indicated the clonal
dissemination of a specific group of tst-positive and agr
class 2 MRSA in Japanese hospitals.
Evaluation of TSST-1 production
We measured the amount of TSST-1 produced in 34 ran-
domly selected strains. The densities of the bands detected
by Western blotting correlated in a semi-log manner with
the amount of rTSST-1 produced. The amounts of TSST-1
secreted into culture supernatants evaluated by compari-
son with the standard curve ranged from 0.8 to 14.0 μg/
ml. Thus, the amount of TSST-1 produced varied 170-fold
among clinical MRSA isolates that were cultured under the
same conditions.
Sequencing of the agr operon
To determine how the structure of the agr locus influences
the amount of TSST-1 secretion, we sequenced this region
in strains 1, 2, 3, 7, 8, 9, 10, 11 and 16, which generated a
TSST-1 concentration range of 0.8 to 14.0 μg/ml (Table 1).
A comparison of the nucleotide sequences from the 9
strains with the corresponding sequence of the agr class 2
reference strain S. aureus SA502A (GenBank accession no.,
AF001782), revealed no relevant changes in the agrD and
agrB regions, whereas 4 strains had allelic variations in the
coding region of agrC, which is the receptor for two com-
ponent regulatory systems. Strain 3 had a point mutation
at nucleotide position 28 of the coding region that
replaced phenylalanine with isoleucine. Strain 10 also
had a point mutation at nucleotide position 651 of the
coding region that replaced glutamine with histidine.
Strain 8 had a 9-nucleotide deletion (nt 495 to 504 of the
agrC coding sequence) that resulted in the deletion of leu-
cine, lysine and isoleucine. Strain 2 had a nucleotide
insertion that caused a frame-shift mutation, which in
turn generated numerous stop codons. Although both
strains 10 and 2 produced large amounts of TSST-1, the
agr locus did not consistently vary in any way from that of
the other strains (Table 2). We also sequenced the pro-
Table 1: Production of TSST-1 evaluated by Western blotting.
No. Strain μg/ml No. Strain μg/ml
1 N315 3.5 ± 0.22 18 2680 1.4 ± 0.19
2A 3 614 ± 1.01 19 2681 1.3 ± 0.05
3 3429 5 ± 0.12 20 2682 1.0 ± 0.25
4 3472 1.3 ± 0.31 21 2683 1.0 ± 0.01
5 3337 1.1 ± 0.20 22 2684 0.8 ± 0.02
6 1785 1.2 ± 0.02 23 2685 1.6 ± 0.23
7 2271 2.0 ± 0.03 24 2686 2.0 ± 0.18
8 3281 4.0 ± 0.22 25 2687 1.6 ± 0.22
9 2932 2.8 ± 0.19 26 2688 7.6 ± 0.07
10 3543 14 ± 1.21 27 2689 9.8 ± 0.28
11 3573 12 ± 0.20 28 2690 3.1 ± 0.16
12 V432 7.0 ± 0.25 29 2701 5.0 ± 1.12
13 V637 7.6 ± 0.30 30 2702 2.8 ± 0.23
14 V666 5.2 ± 0.11 31 2165 4.0 ± 0.13
15 V700 8.0 ± 0.21 32 3624 1.0 ± 0.19
16 V723 1.3 ± 0.34 33 3878 2.2 ± 0.20
17 V694 4.0 ± 0.22 34 3890 6.4 ± 0.08
Strain 1, genome strain. Strains 2 to 34 were randomly selected 
clinical MRSA isolates that were all tst-positive and assigned to agr 
class 2 by PCR. Amounts of TSST-1 varied among strains and ranged 
from 0.8 to 14 μg/ml.BMC Microbiology 2009, 9:52 http://www.biomedcentral.com/1471-2180/9/52
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moter regions of the tst gene, sar (staphylococcal accessory
regulator) and the entire region of sigma factor B of these
9 strains. The sar is another positive regulatory locus for
TSST-1 production that is required for maximal agr expres-
sion and sigma factor B is an important factor that feeds
into the global regulatory network governing the expres-
sion of accessory genes [2,8-10]. No relevant nucleotide
changes were evident in the sequences of both promoter
regions of the tst gene and sar as well as the entire sigma
factor B region (Table 2).
Discussion
The proportion of tst-positive isolates among clinical
MRSA isolates varies from < 20% to 90% according to
country and clinical background [11,12]. The present
study found that over 75% of clinical MRSA isolates car-
ried the tst  gene. This ratio is compatible with that of
recent reports from Japan and it is obviously higher than
those of other countries [11,12]. The ratio of tst-positive
isolates is increasing annually and thus it is important to
understand how TSST-1 production is regulated.
The mere presence of a toxin gene does not mean that the
protein will be expressed and if it is, toxin levels could
widely from strain to strain. In fact, the quantity of Pan-
ton-Valentine Leukocidin (PVL) produced in vitro varies
up to 10-fold among MRSA strains [13].
In the present study, we identified a 170-fold difference in
the amount of TSST-1 produced among MRSA isolates by
Western blotting. Expression of the tst gene is activated by
agr so we sequenced the agr locus of various TSST-1 pro-
ducers to determine whether it is associated with varia-
tions in TSST-1 production. Allelic variations in the agrC
region were identified irrespective of the amount of TSST-
1 produced. One producer of a relatively large amount of
TSST-1 had an insertion of nucleotides in the agrC that
resulted in a frameshift, which in turn generated many
stop codons. Other strains had allelic variations that
resulted in replacement of an amino acid irrespective of
the amount of TSST-1 and a frameshift in the agrC of a
high producer was predicted to generate truncated AgrC.
Therefore, the agr locus is probably not functional with
respect to TSST-1 production in those strains. Recent find-
ings have shown that about 25% of 105 human isolates
are deficient in the production of delta-toxin, indicating
that agr mediated regulation is disrupted [14,15]. These
facts imply that mechanisms other than the agr locus are
involved in TSST-1 production in our isolates. We also
tried to evaluate tst gene expression by Northern blotting,
but the results were not reproducible, perhaps because of
high levels of expression or difficulty in removing nucle-
ase contamination. In addition, the sequences of both the
promoter region of the tst gene and the entire sar locus
were conserved among these strains, indicating that these
regions are not associated with variations in the amount
of TSST-1 production.
The previous and present results indicate that unknown
transcriptional/translational regulatory systems control
TSST-1 production or that multiple regulatory mecha-
nisms are linked in a complex manner to synthesize and
produce toxin. Moreover, secretion mechanisms and pro-
teolytic degradation would also be involved in the
amount of TSST-1 produced.
A recent study has shown that variation in the amount of
extracellular PVL does not correlate with the severity of
infection [13]. In addition, Pragman and Schlievert noted
that the transcriptional analysis of virulence regulators in
animal models in vivo or in human infection do not cor-
relate with transcriptional analysis accomplished in vitro
[16]. From these viewpoints, further investigation is
required to determine whether different amounts of TSST-
1 are produced in vivo and if so, whether they are related
to clinical symptoms of diseases.
Conclusion
The present results suggest that TSST-1 production is not
directly associated with the agr structure, but is instead
Table 2: Summary of nucleotide changes and predicted outcomes of mutations in the agr locus.
Strain number Amount of TSST-1 
produced (μg/ml)
Changes in agrC region 
nucleotide sequence
Predicted outcome tst promoter sarA sigB
1 3.5 NC NC NC NC
2 14 T(321) insertion Frameshift→Truncated AgrC NC NC NC
3 5 T 281A phe→ile NC NC NC
7 2N C N C N C N C
8 4 Δ495~504 Deletion of leu-lys-ile NC NC NC
9 2.8 NC NC NC NC
10 14 G651T glu→his NC NC NC
11 12 NC NC NC NC
16 1.3 NC NC NC NC
Data are from DNA sequencing of agr loci, tst promoter region, sarA and sigB from 9 strains. All mutations were found in agrC. NC, no change.BMC Microbiology 2009, 9:52 http://www.biomedcentral.com/1471-2180/9/52
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controlled by unknown transcriptional/translational reg-
ulatory systems, or synthesized by multiple regulatory
mechanisms that are interlinked in a complex manner.
Methods
Bacterial strains
Of 152 clinical MRSA isolates that we analyzed, 66 were
randomly selected from the nationwide MRSA collection
representing various regions of Japan in 2003, and the
remainder was isolated from the bloodstream of patients
in different wards at a university hospital between 1996
and 2003.
Detection of the tst gene and agr-genotyping by PCR
Bacterial chromosomal DNA was extracted after overnight
growth on Luria Bertani agar as described [17]. We
detected the tst gene by PCR amplification using the spe-
cific primers, TGT AGA TCT ACA AAC GAT AAT ATA AAG
GAT (forward) and ATT AAG CTT AAT TAA TTT CTG CTT
CTA TAG TT (reverse). Genes were amplified by denatur-
ation for 5 min at 94°C followed by 30 cycles of 30 s at
94°C, 30 s at 52°C, 60 s at 72°C and a final extension at
72°C for 5 min in a 25-μl mixture, comprising 1 μl tem-
plate DNA, 0.2 mM dNTP mix, 1.5 mM 10× Ex buffer
(Takara, Tokyo, Japan), 1.25 U Ex Taq (Takara) and 0.5
μM each of the forward and reverse primers. The agr class
was determined by PCR amplification of the hypervaria-
ble domain of the agr locus using specific oligonucleotide
primers as described [18].
Preparation of recombinant partial TSST-1 and anti TSST-
1 antibody
Fragments of the tst gene DNA were amplified by PCR
using primers with BglII-HindIII restriction sites (Table 3).
Amplified 280-bp DNA fragments were subcloned into
the pBluescriptII plasmid, digested with EcoRV and trans-
formed into Escherichia coli DH5α, which was then
digested with BglII and HindIII. The BglII -HindIII frag-
ment of E. coli DH5α was subcloned into the BamHI-Hin-
dIII site of pQE30 (Qiagen, Hilden, Germany) and
transformed into E. coli JM109. His-tagged recombinant
partial TSST-1 protein (rTSST-1) was expressed in E. coli
JM109 and the cells were lysed using a French press (SLM
Instruments, Inc., IL, USA). Recombinant TSST-1 was
purified from the cell lysate using Ni-NTA agarose (Qia-
gen) according to the manufacturer's instructions. Puri-
fied rTSST-1 (100 μg/ml) was emulsified with an equal
volume of Freund's complete adjuvant (Difco, NJ, USA)
and subcutaneously injected into Japanese white rabbits
to generate anti-TSST-1 antiserum. A second antibody
response was elicited by immunization with the antigen
alone and serum was collected.
Quantitation of TSST-1 by Western blotting
Strains were incubated in 3 ml LB broth overnight and
then 100 μl cultures were transferred into 5 ml fresh LB
broth and incubated at 37°C with rotary shaking at 150
rpm. Bacterial growth was monitored until the cell density
reached the early stationary phase. Culture supernatant
was obtained by centrifugation at 8000 × g for 15 min to
precipitate bacterial cells. Total exoproteins precipitated
from the culture supernatant with 10% trichloroacetic
acid (TCA) were washed with cold acetone and dissolved
in 100 μl of Laemmli sample buffer [19]. Proteins were
resolved by electrophoresis and then Western blotted
according to standard procedures with the minor modifi-
cation described by Whiting et al [20]. Serially diluted
rTSST-1 samples were western blotted to produce a stand-
ard curve. The individual experiments to determine TSST-
1 expression for each strain were repeated three times. The
density of each immunostained band was evaluated using
Imagemaster 1D Elite ver.3.00 (Amersham Bioscience,
Tokyo, Japan) and mean values were adopted.
Sequence analysis of a variant agr locus
Table 1 lists the specific primers used to sequence the
entire region of agr A, B, C, and D. The region was ampli-
fied by PCR under the same conditions as described for
detection of the tst gene. The products were purified using
a QIAquick PCR purification kit (Qiagen) and sequenced
on a CEQ 2000 DNA analysis system (Beckman Coulter,
Fullerton, CA, USA) using Beckman Dye terminator cycle
sequencing kits (CEQ DTCS kit, Tokyo, Japan) according
to the manufacturer's instructions.
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